UCB: upbeat after lupus data

(CercleFinance.com) - UCB climbs 3% in Brussels following the announcement, with its partner Biogen, of positive top-line results from the PHOENYCS GO phase 3 study evaluating their dapirolizumab pegol, in people with moderate-to-severe systemic lupus erythematosus (SLE).


The drug candidate, in addition to standard therapy, met the primary endpoint by demonstrating greater improvement in moderate-to-severe disease activity after 48 weeks, compared with placebo in addition to standard therapy.

Clinical improvements were observed across key secondary endpoints measuring disease activity and relapses. The safety profile of dapirolizumab pegol was generally consistent with previous studies.

Copyright (c) 2024 CercleFinance.com. All rights reserved.